Financial Performance - Revenue for Q1 2024 was CNY 91,441,252.36, a decrease of 18.85% compared to CNY 112,684,910.79 in the same period last year[5] - Net profit attributable to shareholders was CNY 14,391,514.75, down 34.92% from CNY 22,115,265.70 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 91,441,252.36, a decrease of 18.8% compared to CNY 112,684,910.79 in Q1 2023[19] - Net profit for Q1 2024 was CNY 15,474,779.84, a decline of 35.8% from CNY 24,073,789.17 in Q1 2023[20] - The company reported a basic and diluted earnings per share of CNY 0.05 for Q1 2024, compared to CNY 0.08 in Q1 2023[21] - Total operating costs for Q1 2024 were CNY 71,751,172.33, down 17.6% from CNY 87,034,936.18 in the previous year[19] Cash Flow and Liquidity - Operating cash flow increased by 27.78% to CNY 10,870,539.98, compared to CNY 8,507,031.19 in Q1 2023[5] - The company’s cash flow from operating activities showed a significant improvement, indicating better liquidity management[20] - Total cash inflow from operating activities is ¥99,050,081.27, down 2.9% from ¥101,952,290.69 in the previous period[22] - Cash outflow from operating activities decreased to ¥88,179,541.29 from ¥93,445,259.50, reflecting a reduction of 5.6%[22] - The net cash flow from operating activities for the current period is ¥10,870,539.98, an increase of 27.8% compared to ¥8,507,031.19 in the previous period[22] - Cash inflow from financing activities is ¥24,000,000.00, with a net cash flow of ¥15,790,316.69, compared to -¥2,989,717.62 in the previous period[24] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 692,367,956.43, reflecting a 2.03% increase from CNY 678,594,899.40 at the end of the previous year[5] - The total non-current assets amounted to CNY 417,526,458.27, an increase from CNY 411,317,030.68 in the previous year[17] - Total liabilities decreased slightly to CNY 220,713,856.77 in Q1 2024 from CNY 222,334,653.65 in Q1 2023[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 31,938[10] - The top shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., holds 20.76% of the shares, totaling 55,044,822 shares[11] - The second-largest shareholder, Beijing Century Tianfu Venture Capital Center, holds 5.80% of the shares, totaling 15,366,266 shares[11] - The company is actively managing its shareholder structure, with notable participation in financing and securities lending activities by major shareholders[11] Investment and Expenses - Cash flow from investing activities showed a net outflow of CNY 34,622,805.36, a 505.84% increase in outflow compared to CNY -5,714,848.55 in the previous year[8] - Research and development expenses for Q1 2024 were CNY 7,484,200.53, down from CNY 9,567,734.69 in Q1 2023, reflecting a 21.8% reduction[19] - The company invested ¥34,622,805.36 in fixed assets, a substantial increase from ¥5,725,426.55 in the previous period[24] Other Financial Metrics - The weighted average return on equity decreased to 2.73% from 4.45% year-on-year[5] - Other income decreased by 59.14% to CNY 1,218,321.80, primarily due to reduced government subsidies[7] - The company paid ¥34,795,280.36 in employee compensation, slightly increasing from ¥34,406,341.98[22] - Tax payments increased significantly to ¥7,257,699.29 from ¥2,900,501.76, marking a rise of 150.5%[22] Inventory and Receivables - Accounts receivable increased to ¥74,827,102.21 from ¥61,142,630.83, showing a growth of about 22.4%[15] - The company reported a significant increase in accounts receivable, which may indicate improved sales performance or extended credit terms[15] - Prepayments rose to ¥10,086,994.43 from ¥7,215,658.54, indicating an increase of approximately 39.5%[15] - Inventory decreased to ¥68,970,276.51 from ¥71,601,478.41, reflecting a decline of about 3.6%[15] - Total current assets increased to ¥274,841,498.16 from ¥267,277,868.72, marking a growth of approximately 2.1%[15] Corporate Actions - The company has extended the validity period for the issuance of A-shares to specific investors by 12 months, maintaining other terms unchanged[13] - The company has not yet audited the first quarter report[25]

证券代码：300238 证券简称：冠昊生物 公告编号：2024-022 冠昊生物科技股份有限公司 关于控股股东股份被司法再冻结及轮候冻结的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 截至公告披露日，上述股东及其一致行动人所持股份累计被轮候冻结的情 近日，冠昊生物科技股份有限公司（以下简称"公司"）收到公司控股股 东广东知光生物科技有限公司（以下简称"广东知光"）通知，获悉其所持有 本公司的股份存在被司法再冻结及轮候冻结的情况，具体事项如下： 一、 股东股份被冻结基本情况 | 股东名称 | 是否为第一 大股东及一 | 本次冻结股 | 占其所持 | 占公司总 | 是否为 限售股 | 起始日 | 到期日 | 司法冻结执行 | 原因 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 致行动人 | 份数量 | 股份比例 | 股本比例 | 及限售 | | | 人名称 | | | | | | | | 类型 | | | | | | 广东知光生物 | 是 | 14,650,000 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2024-021 冠昊生物科技股份有限公司 | | | 持股比 | 本次质押 | 本次质押 | 占其所 | 占公司 | 已质押股份情况 已质押股 | 占已质 | 未质押股份情况 未质押股 | 占未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 | | 前质押股 | 后质押股 | 持股份 | 总股本 | | | | | | | | 例 | | | | | 份限售和 | 押股份 | 份限售和 | 质押 | | | | | 份数量 | 份数量 | 比例 | 比例 | | | | | | | | | | | | | 冻结数量 | 比例 | 冻结数量 | 股份 | | | | | | | | | | | | 比例 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 广东知光生物 科技有限公司 | 55,044,822 | 20.76% | 40,394,8 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2024-020 冠昊生物科技股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 1、冠昊生物科技股份有限公司（以下简称"公司"）分别于2024年3月6日发 出《关于召开2023年年度股东大会的通知》、2024年3月22日发出《关于召开2023 年年度股东大会的提示性公告》（详见中国证监会指定的创业板信息披露网站巨潮 资讯网（www.cninfo.com.cn））。 （1）会议召开时间：2024年3月26日下午14:30。 （2）会议召开地点：广州市黄埔区玉岩路12号公司会议室。 （3）会议召开方式：采取现场投票与网络投票相结合的方式。现场会议召开 时间：2024年3月26日下午14:30。网络投票时间：通过深圳证券交易所交易系统进 行网络投票的时间为：2024年3月26日上午9:1 ...

北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌鲁木齐 郑 州 石 家 庄 合 肥 海 南 青 岛 南 昌 大 连 银 川 拉 孜 香 港 巴 黎 马德里 斯 德 哥 尔 摩 纽 约 广州市天河区珠江东路 28 号越秀金融大厦 38 楼 邮编：510623 电话：(+86)(20) 3879 9345 传真：(+86)(20) 3879 9345-200 国浩律师(广州)事务所 关于冠昊生物科技股份有限公司 2023 年年度股东大会的法律意见 根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受冠 昊生物科技股份有限公司(以下简称"冠昊生物")的委托，指派李彩霞、杨雪莹 律师(以下简称"本所律师")出席冠昊生物 2023 年年度股东大会(以下简称"本 次股东大会")，对本次股东大会的召集与召开程序、出席会议人员与召集人的 资格、表决程序与表决结果等重要事项出具法律意见。 (二)本次股东大会的召开 本次股东大会按 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2024-019 冠昊生物科技股份有限公司 关于召开 2023 年年度股东大会的提示性公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 冠昊生物科技股份有限公司(以下简称"公司")于 2024 年 3 月 6 日在中国 证监会指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关 于召开 2023 年年度股东大会的通知》（公告编号：2024-013）。本次股东大会采 用现场投票和网络投票相结合的方式召开，现将本次股东大会的有关事宜提示如 下： 一、召开会议的基本情况 （五）会议召开方式：本次会议采取现场投票与网络投票相结合的方式，本 公 司 将 通 过 深 圳 证 券 交 易 所 交 易 系 统 和 互 联 网 投 票 系 统 （http://wltp.cninfo.com.cn）向股东提供网络形式的投票平台，股东可以在网络投 票时间内通过上述系统行使表决权。 参加股东大会的方式：公司股东只能选择现场投票（现场投票可以委托代理 人代为投票）和网络投票中的一种表决方式，如果 ...

证券代码：300238 证券简称：冠昊生物 冠昊生物科技股份有限公司 投资者关系活动记录表 编号：2024-001 □特定对象调研 □分析师会议 投资者关系活 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 动类别 □现场参观 □其他 参与单位名称 参与冠昊生物2023年度业绩网上说明会的投资者 及人员姓名 时间 2024年 3月 15日 15:00-17:00 地点 全景网“投资者关系互动平台”（http://ir.p5w.net） 董事长、总经理 张永明先生 上市公司接待 独立董事 韩俊梅女士 人员姓名 副总经理、董事会秘书 徐庆荣先生 财务负责人 张伟坤先生 为便于广大投资者能够更加全面、深入了解公司的生产经营 情况，公司于 2024 年 3 月 15 日下午 15:00-17:00 在全景网投资 ...

地址：深圳市福田区益田路 6001 号太平金融大厦 22 楼 邮编：518038 地址：重庆市江北区金沙门路 32 号西南证券总部大楼 21 楼 邮编：400025 重庆 地址：上海市浦东新区陆家嘴 21 世纪大厦 10 楼 邮编：200120 冠昊生物（300238）2023 年报点评 西南证券研究发展中心 上海 本维莫德较快增长，生物材料新产品快速放量 [Table_Summary 事件：公司发布] 2023 年报，实现营业收入 4 亿元(+7.1%)；归属于上市公司股 东的净利润为 0.3亿元。2023年第四季度实现营业收入 1亿元(+14.3%)；归属 于上市公司股东的净利润为亏损 1026.6 万元。 风险提示：本维莫德放量不及预期风险、耗材带量采购未中标或降价超预期风 险、研发失败风险。 1 [Table_QuotePic] 相对指数表现 -30% -6% 19% 43% 67% 91% 23/3 23/5 23/7 23/9 23/11 24/1 24/3 冠昊生物 沪深300 [ T able_StockInfo] 2024 年 03 月 09 日 证券研究报告•2023 年报点评 买入 （维 ...

Financial Performance - The company’s operating revenue for 2023 was ¥404,178,697.25, representing a 7.13% increase compared to ¥377,285,014.20 in 2022[24]. - The net profit attributable to shareholders for 2023 was ¥31,005,798.58, a significant turnaround from a loss of ¥307,836,656.76 in 2022, marking a 110.07% increase[24]. - The net profit after deducting non-recurring gains and losses was ¥30,555,396.54, up 109.24% from the previous year[24]. - The total assets at the end of 2023 were ¥678,594,899.40, a 1.24% increase from ¥670,209,400.26 at the end of 2022[24]. - The net assets attributable to shareholders increased by 7.26% to ¥520,593,839.11 from ¥485,310,208.77 in 2022[24]. - The company reported a basic earnings per share of ¥0.12 for 2023, compared to a loss of ¥1.16 in 2022, reflecting a 110.34% improvement[24]. - The weighted average return on equity for 2023 was 6.16%, a significant recovery from -48.51% in 2022, indicating a 54.66% increase[24]. - The company achieved a total revenue of 404 million yuan in 2023, representing a year-on-year increase of 7.13%[49]. - The medical device segment generated ¥289,097,618.47, accounting for 71.53% of total revenue, with a slight increase of 1.01% from the previous year[59]. - The pharmaceutical segment saw significant growth, with revenue of ¥49,438,451.80, up 43.91% from ¥34,354,885.49 in 2022, representing 12.23% of total revenue[59]. Research and Development - The company is focused on continuous innovation in the biopharmaceutical industry, emphasizing the development of biomaterials, pharmaceuticals, and advanced medical technologies[36]. - The company has established a GMP-compliant immune cell and stem cell preparation technology system, ensuring quality standards are met[42]. - The company is actively advancing the application for a "Human Genetic Resource Sample Bank" to support future drug development and biomedical research[46]. - The company is conducting clinical research for multiple new products, including a biological artificial liver and a disposable PRP preparation device, aiming for product registration and market launch[70]. - The company has initiated a national key R&D project focused on joint cartilage regeneration materials, aiming to drive innovation in regenerative research[70]. - The company has obtained 14 new patents during the reporting period, including 2 foreign patents and 12 domestic patents, bringing the total to 132 authorized patents[71]. - Research and development expenses decreased by 11.90% to ¥44.50 million, attributed to the progress of ongoing projects[69]. - R&D investment amounted to ¥49,374,790.28 in 2023, representing 12.22% of operating revenue, a decrease from 15.35% in 2022[71]. Market and Industry Trends - The medical device industry in China is expected to reach a revenue of 1.31 trillion yuan in 2023, maintaining a double-digit growth rate and ranking second globally[37]. - The pharmaceutical industry in China has seen an average annual revenue growth of 9.3% and profit growth of 11.3% since the 14th Five-Year Plan, with R&D investment increasing by over 20% annually[39]. - The global demand for medical devices is expected to continue growing due to population aging and increasing health needs, presenting opportunities for the company[37]. - The company is focusing on expanding its core business segments: biomaterials, pharmaceuticals, and cell therapy, to adapt to market challenges and opportunities[44]. Corporate Governance - The company has established a comprehensive internal management and control system, continuously improving its governance structure[107]. - The board of directors consists of 5 members, including 2 independent directors, ensuring compliance with relevant regulations[113]. - The company emphasizes investor relations management, providing multiple communication channels for investor engagement[117]. - The company held 4 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[111]. - The company has established a risk control department to enhance internal control and risk management[162]. - The company has implemented a comprehensive internal control system to ensure effective governance and compliance[163]. Legal and Compliance - The company has faced administrative penalties for failing to disclose significant litigation and subsidiary distribution rights termination in a timely manner[198]. - A warning letter was issued by the China Securities Regulatory Commission regarding the company's disclosure practices[198]. - The company is committed to improving compliance awareness and preventing similar issues from occurring in the future[200]. - The company is involved in significant litigation with an amount of CNY 10.51 million, currently in the second instance[196]. - The company is also involved in arbitration with an amount of CNY 5,392.92, with hearings scheduled for April 22, 2024[197]. Employee and Social Responsibility - The company has implemented measures to create a fair and harmonious work environment, focusing on employee potential and sustainable development[172]. - The company adheres to labor laws, ensuring employee rights and benefits through a comprehensive social insurance system, including pension, medical, and unemployment insurance[173]. - The company actively participates in charitable activities and has been recognized as a "Charity Heart Enterprise" by the Guangzhou Huangpu District Social Construction Promotion Association[178]. - The company promotes a healthy work environment through various employee engagement activities, enhancing morale and creativity[173]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 20% to 1.44 billion RMB[140]. - The company aims to improve operational efficiency, targeting a 5% reduction in production costs by the end of the next fiscal year[140]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 20% over the next three years[140]. - The company plans to actively participate in centralized procurement policies to improve bidding strategies and expand sales channels, aiming for a diversified product range and a new breakthrough in market share[96].

冠昊生物科技股份有限公司 董事会薪酬与考核委员会实施细则 第一条 为进一步健全冠昊生物科技股份有限公司(以下简称"公司")董事及 高级管理人员的薪酬管理和考核制度，优化公司激励与约束机制，完善公司治理结 构，根据《公司法》《上市公司治理准则》《上市公司独立董事管理办法》《公司 章程》及其他法律法规、规范性文件等有关规定，公司设立董事会薪酬与考核委员 会，并制定本细则。 第二条 董事会薪酬与考核委员会是董事会按照《公司章程》设立的专门工作 机构，主要负责制定、审核公司董事及高级管理人员的薪酬方案和考核标准，对董 事和高级管理人员的薪酬、股权激励计划、员工持股计划等向董事会提出建议，委 员会对董事会负责，向董事会报告工作。 第三条 本细则所称"董事"是指在公司领取报酬的董事，不包括独立董事和 其他外部董事；"高级管理人员"是指董事会聘任的总经理、副总经理、董事会秘 书、财务负责人及《公司章程》规定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由 3 名董事组成，其中独立董事应当过半数。 第五条 薪酬与考核委员会委员由董事长、1/2 以上独立董事或者全体董事的 1/3 提名，并由董事会过半数选 ...